157 related articles for article (PubMed ID: 17230517)
1. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.
Furchert SE; Lanvers-Kaminsky C; Juürgens H; Jung M; Loidl A; Frühwald MC
Int J Cancer; 2007 Apr; 120(8):1787-94. PubMed ID: 17230517
[TBL] [Abstract][Full Text] [Related]
2. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC.
Li XN; Shu Q; Su JM; Perlaky L; Blaney SM; Lau CC
Mol Cancer Ther; 2005 Dec; 4(12):1912-22. PubMed ID: 16373706
[TBL] [Abstract][Full Text] [Related]
4. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni.
Dubois F; Caby S; Oger F; Cosseau C; Capron M; Grunau C; Dissous C; Pierce RJ
Mol Biochem Parasitol; 2009 Nov; 168(1):7-15. PubMed ID: 19538992
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
7. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.
Knipstein JA; Birks DK; Donson AM; Alimova I; Foreman NK; Vibhakar R
Neuro Oncol; 2012 Feb; 14(2):175-83. PubMed ID: 22156471
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.
Aztopal N; Erkisa M; Erturk E; Ulukaya E; Tokullugil AH; Ari F
Chem Biol Interact; 2018 Jan; 280():51-58. PubMed ID: 29225137
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
Dong XF; Song Q; Li LZ; Zhao CL; Wang LQ
Neuro Endocrinol Lett; 2007 Dec; 28(6):775-80. PubMed ID: 18063935
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors promote osteoblast maturation.
Schroeder TM; Westendorf JJ
J Bone Miner Res; 2005 Dec; 20(12):2254-63. PubMed ID: 16294278
[TBL] [Abstract][Full Text] [Related]
12. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
[TBL] [Abstract][Full Text] [Related]
13. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
Facchetti F; Previdi S; Ballarini M; Minucci S; Perego P; La Porta CA
Apoptosis; 2004 Sep; 9(5):573-82. PubMed ID: 15314285
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
Dalgard CL; Van Quill KR; O'Brien JM
Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Sonnemann J; Kumar KS; Heesch S; Müller C; Hartwig C; Maass M; Bader P; Beck JF
Int J Oncol; 2006 Mar; 28(3):755-66. PubMed ID: 16465382
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells.
Papi A; Ferreri AM; Rocchi P; Guerra F; Orlandi M
Anticancer Res; 2010 Feb; 30(2):535-40. PubMed ID: 20332466
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
Kerl K; Ries D; Unland R; Borchert C; Moreno N; Hasselblatt M; Jürgens H; Kool M; Görlich D; Eveslage M; Jung M; Meisterernst M; Frühwald M
BMC Cancer; 2013 Jun; 13():286. PubMed ID: 23764045
[TBL] [Abstract][Full Text] [Related]
18. Increased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition.
Michaelis M; Suhan T; Reinisch A; Reisenauer A; Fleckenstein C; Eikel D; Gümbel H; Doerr HW; Nau H; Cinatl J
Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3451-7. PubMed ID: 16123451
[TBL] [Abstract][Full Text] [Related]
19. Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors.
Muscat A; Popovski D; Jayasekara WS; Rossello FJ; Ferguson M; Marini KD; Alamgeer M; Algar EM; Downie P; Watkins DN; Cain JE; Ashley DM
Clin Cancer Res; 2016 Jul; 22(14):3560-70. PubMed ID: 26920892
[TBL] [Abstract][Full Text] [Related]
20. A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Sredni ST; Suzuki M; Yang JP; Topczewski J; Bailey AW; Gokirmak T; Gross JN; de Andrade A; Kondo A; Piper DR; Tomita T
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28398638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
